Insider · CIK 0000886982
Goldman Sachs Group Inc
Files at PBLA (Panbela Therapeutics, Inc.), QRTEA (Qurate Retail, Inc.), SG (Sweetgreen, Inc.), STER (Sterling Check Corp.), SHCO (Soho House & Co Inc.), MRLN (Merlin, Inc.), ATTO (Attovia Therapeutics, Inc.), APUR (Aperture AC). First filing Nov 13, 2023, latest Aug 28, 2026.
In brief
Goldman Sachs Group Inc files SEC Form 4 as 10% owner at QRTEA (Qurate Retail, Inc.), and also at ATTO (Attovia Therapeutics, Inc.), STER (Sterling Check Corp.), SHCO (Soho House & Co Inc.), MRLN (Merlin, Inc.) and 3 more. Since Nov 13, 2023, Goldman Sachs Group Inc has reported 7 open-market buys worth $24M and 10 open-market sells worth $35M, the latest filed on Aug 28, 2026.
A track record needs three past buys with six months of prices behind them; Goldman Sachs Group Inc has 2, so none is measured yet.
The newest scored trade: bought $10M of ATTO on Aug 5, 2026, filed Aug 28, 2026, scored 56 (moderate). In the last 12 months: 6 buys worth $24M and 8 sells worth $35M.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
ATTO: Attovia Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
MRLN: Merlin, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 56Moderate | Attovia Therapeutics, Inc. | $10M 585,000 shares | - | - | |
| 61Notable | Attovia Therapeutics, Inc. | $2.3M 105,807 shares | -124% | - | |
| 56Moderate | Attovia Therapeutics, Inc. | $10M 585,000 shares | - | - | |
| 61Notable | Attovia Therapeutics, Inc. | $2.3M 105,807 shares | -124% | - | |
| 12Weak | APURsell Aperture AC | $475 48 shares | -0% | - | |
| 17Weak | QRTEAbuy Qurate Retail, Inc. | $5,503 10,006 shares | +134% | - | |
| 32Weak | QRTEAsell Qurate Retail, Inc. | $5,082 9,964 shares | -57% | - | |
| 17Weak | QRTEAbuy Qurate Retail, Inc. | $5,503 10,006 shares | +97% | - | |
| 22Weak | QRTEAsell Qurate Retail, Inc. | $5,082 9,964 shares | -49% | - | |
| 43Moderate | SGbuy Sweetgreen, Inc. | $3.4M 594,553 shares | +5% | +21% from low-75% from high | |
| 8Weak | MRLNbuy Merlin, Inc. | $47k 4,328 shares | +0% | - | |
| 29Weak | MRLNsell Merlin, Inc. | $53k 4,872 shares | -0% | - | |
| 42Moderate | SHCOsell Soho House & Co Inc. | $15M 1,666,666 shares | -11% | - | |
| 42Moderate | SHCOsell Soho House & Co Inc. | $15M 1,666,666 shares | -11% | - | |
| 10Weak | Sterling Check Corp. | $2,110 157 shares | +0% | - | |
| 20Weak | Sterling Check Corp. | $2,132 157 shares | -0% | - | |
| 24Weak | PBLAsell Panbela Therapeutics, Inc. | $52k 72,874 shares | -15% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 28, 2026 | ATTO Attovia Therapeutics, Inc. | 105,807 0.25% of outstanding | $2.2M | Aug 5, 2026 | none |
Transactions
The newest 50 of 145 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnotes | +85,000 | $21.00 | $1.8M | 85,000 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -988 | $22.03 | $22k | 84,012 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -447 | $21.87 | $9,776 | 83,565 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,332 | $22.03 | $29k | 82,233 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -200 | $22.05 | $4,410 | 82,033 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,556 | $22.06 | $34k | 80,477 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -3,402 | $22.02 | $75k | 77,075 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -200 | $22.10 | $4,420 | 76,875 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -480 | $21.55 | $10k | 76,395 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -100 | $22.11 | $2,211 | 76,295 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -753 | $21.97 | $17k | 75,542 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -672 | $22.02 | $15k | 74,870 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -6,970 | $22.03 | $154k | 67,900 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -400 | $22.02 | $8,808 | 67,500 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,180 | $21.84 | $26k | 66,320 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,040 | $22.05 | $23k | 65,280 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -300 | $20.84 | $6,252 | 64,980 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -443 | $21.78 | $9,649 | 64,537 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -200 | $22.05 | $4,410 | 64,337 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -700 | $22.07 | $15k | 63,637 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,163 | $22.19 | $26k | 62,474 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -100 | $21.99 | $2,199 | 62,374 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -6,763 | $21.61 | $146k | 55,611 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -76,418 | $21.04 | $1.6M | 0 | Aug 28, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Common Stockindirect: See Footnotes | +1,957,134 | $0.00 | $0 | 2,042,134 | Aug 28, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Common Stockindirect: See Footnotes | +478,498 | $0.00 | $0 | 2,520,632 | Aug 28, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnotes | +500,000 | $17.00 | $8.5M | 3,020,632 | Aug 28, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -18,181,830 | $0.00 | $0 | 0 | Aug 28, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -4,445,275 | $0.00 | $0 | 0 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +2,872 | $21.22 | $61k | 2,872 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +28,717 | $21.22 | $609k | 31,589 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +11,488 | $21.22 | $244k | 43,077 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +45,588 | $21.27 | $970k | 88,665 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +11,398 | $21.27 | $242k | 100,063 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +5,744 | $21.22 | $122k | 105,807 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnotes | +85,000 | $21.00 | $1.8M | 85,000 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -988 | $22.03 | $22k | 84,012 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -447 | $21.87 | $9,776 | 83,565 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,332 | $22.03 | $29k | 82,233 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -200 | $22.05 | $4,410 | 82,033 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,556 | $22.06 | $34k | 80,477 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -3,402 | $22.02 | $75k | 77,075 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -200 | $22.10 | $4,420 | 76,875 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -480 | $21.55 | $10k | 76,395 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -100 | $22.11 | $2,211 | 76,295 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -753 | $21.97 | $17k | 75,542 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -672 | $22.02 | $15k | 74,870 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -6,970 | $22.03 | $154k | 67,900 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -400 | $22.02 | $8,808 | 67,500 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,180 | $21.84 | $26k | 66,320 | Aug 13, 2026 |
Questions about Goldman Sachs Group Inc
Answered from the filings on this page, as of the latest one.
Is Goldman Sachs Group Inc buying or selling?
In the last 12 months Goldman Sachs Group Inc reported 6 open-market buys worth $24M and 8 open-market sells worth $35M on SEC Form 4; the latest was bought $10M of ATTO on Aug 5, 2026. Grants, option exercises and tax withholding are not counted.
How did Goldman Sachs Group Inc's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Goldman Sachs Group Inc has 2.
Where does Goldman Sachs Group Inc file Form 4?
Goldman Sachs Group Inc has filed Form 4 at QRTEA (Qurate Retail, Inc.); ATTO (Attovia Therapeutics, Inc.); STER (Sterling Check Corp.); SHCO (Soho House & Co Inc.); MRLN (Merlin, Inc.) and 3 more. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.